Research ArticleBone

JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function

See allHide authors and affiliations

Science Translational Medicine  12 Feb 2020:
Vol. 12, Issue 530, eaay4447
DOI: 10.1126/scitranslmed.aay4447

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Boosting osteoblasts to battle bone erosion

Inhibitors of Janus kinase (JAK) reduce inflammation and are approved to treat rheumatoid arthritis; however, the direct effects of inhibitors on bone remain unclear. Adam et al. found that JAK inhibitors increased bone mass in mice under homeostatic conditions and mitigated bone loss in a mouse model of osteoporosis. Mice with inflammatory bone loss mimicking rheumatoid arthritis had reduced bone erosions after treatment with JAK inhibitors, and two patients with rheumatoid arthritis treated with tofacitinib showed similar results. The authors determined that JAK inhibitors induced bone repair by altering gene expression and increasing activity of osteoblasts, supporting use of inhibitors as potential osteoanabolics.

View Full Text

Stay Connected to Science Translational Medicine